hist162443 No action taken on February 14, 2023.

hist162444 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-035

Relating to Excluding 6-beta-Naltrexol.

hist162441 No action taken on February 14, 2023.

hist162442 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-036

Relating to scheduling Fospropofol.

hist162439 No action taken on February 14, 2023.

hist162440 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-037

Relating to scheduling Embutramide.

hist162437 No action taken on February 14, 2023.

hist162438 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-038

Relating to scheduling Perampanel.

hist162435 No action taken on February 14, 2023.

hist162436 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-039

Relating to scheduling Lacosamide.

hist162433 No action taken on February 14, 2023.

hist162434 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-040

Relating to transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, immediate precursors to phencyclidine, also known as PCP.

hist162431 No action taken on February 14, 2023.

hist162432 Referred to the joint committee for review of Administrative Rules, February 14, 2023.

Senate Clearinghouse Rule 22-043

Relating to telehealth.

hist162429 No action taken on February 14, 2023.